Biocryst Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Biocryst Pharmaceuticals Inc share price today is $10.04, up -1.12%. The stock opened at $9.77 against the previous close of $9.81, with an intraday high of $10.31 and low of $9.64.

Biocryst Pharmaceuticals Inc Share Price Chart

Biocryst Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Biocryst Pharmaceuticals Inc Share Price Performance

$10.04 -0.0112(-1.12%) BCRX at 23 Mar 2026 12:10 PM Drug Manufacturers - Specialty & Generic
Lowest Today 9.64
Highest Today 10.31
Today’s Open 9.77
Prev. Close 9.81
52 Week High 11.31
52 Week Low 6.00
Day’s Range: Low 9.64 High 10.31
52-Week Range: Low 6.00 High 11.31
1 day return -
1 Week return +4.34
1 month return +27.72
3 month return +27.89
6 month return +22.96
1 year return +20.89
3 year return +22.57
5 year return -17.48
10 year return -

Biocryst Pharmaceuticals Inc Institutional Holdings

Vanguard Group Inc 8.88

BlackRock Inc 8.47

RA Capital Management, LLC 6.31

Deerfield Management Co 5.72

State Street Corp 3.91

Kynam Capital Management, LP 3.73

Vanguard Total Stock Mkt Idx Inv 2.91

State Street® SPDR® S&P® Biotech ETF 2.54

UBS Group AG 2.38

iShares Russell 2000 ETF 2.28

Morgan Stanley - Brokerage Accounts 2.07

Geode Capital Management, LLC 2.02

Two Sigma Investments LLC 1.80

Two Sigma Advisers, LLC 1.63

Nuveen, LLC 1.44

GW&K Investment Management, LLC 1.26

Baker Bros Advisors LP 1.13

The Goldman Sachs Group Inc 1.08

ACAP Strategic A 1.08

Vanguard Small Cap Index 1.05

Vanguard Strategic Equity Inv 1.03

Vanguard Institutional Extnd Mkt Idx Tr 1.02

BNP Paribas Arbitrage, SA 1.01

Fisher Asset Management, LLC 0.98

JPMorgan Chase & Co 0.90

Vestal Point Capital LP 0.90

abrdn Healthcare Investors 0.88

Qube Research & Technologies 0.86

Fidelity Small Cap Index 0.82

Hood River Small-Cap Growth Instl 0.79

iShares Russell 2000 Growth ETF 0.70

iShares Biotechnology ETF 0.68

Invesco S&P 500 ETF 0.67

Vanguard Explorer Inv 0.62

Vanguard Small Cap Growth Index Inv 0.58

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

Janus Henderson Hrzn Biotec E2 USD 0.54

CREF Total Global Stock Account R3 0.52

Fidelity Extended Market Index 0.49

Biotech Growth Ord 0.47

Biocryst Pharmaceuticals Inc Market Status

Strong Buy: 6

Buy: 5

Hold: 1

Sell: 0

Strong Sell: 0

Biocryst Pharmaceuticals Inc Fundamentals

Market Cap 1872.69 M

PB Ratio 56.5858

PE Ratio 0.0

Enterprise Value 2601.91 M

Total Assets 514.16 M

Volume 13148754

Biocryst Pharmaceuticals Inc Company Financials

Annual Revenue FY24:450712000 450.7M, FY23:317556000 317.6M, FY22:270827000 270.8M, FY21:157170000 157.2M, FY20:17812000 17.8M

Annual Profit FY24:438443000 438.4M, FY23:312036000 312.0M, FY22:264233000 264.2M, FY21:149906000 149.9M, FY20:16136000 16.1M

Annual Net worth FY24:-88881000 -88.9M, FY23:-236349000 -236.3M, FY22:-247117000 -247.1M, FY21:-184062000 -184.1M, FY20:-196567000 -196.6M

Quarterly Revenue Q3/2025:159395000 159.4M, Q2/2025:163353000 163.4M, Q1/2025:145534000 145.5M, Q3/2024:117085000 117.1M, Q2/2024:109332000 109.3M

Quarterly Profit Q3/2025:156873000 156.9M, Q2/2025:160555000 160.6M, Q1/2025:140966000 141.0M, Q3/2024:113857000 113.9M, Q2/2024:107278001 107.3M

Quarterly Net worth Q3/2025:12899000 12.9M, Q2/2025:5085000 5.1M, Q1/2025:32000 0.0M, Q3/2024:-14033000 -14.0M, Q2/2024:-12674000 -12.7M

About Biocryst Pharmaceuticals Inc & investment objective

Company Information BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Organisation Drug Manufacturers - Specialty & Generic

Employees 435

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Charles K. Gayer

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Biocryst Pharmaceuticals Inc FAQs

What is the share price of Biocryst Pharmaceuticals Inc today?

The current share price of Biocryst Pharmaceuticals Inc is $10.04.

Can I buy Biocryst Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Biocryst Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Biocryst Pharmaceuticals Inc shares in India?

You can easily invest in Biocryst Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Biocryst Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Biocryst Pharmaceuticals Inc?

Biocryst Pharmaceuticals Inc has a market cap of $1872.69 M.

In which sector does Biocryst Pharmaceuticals Inc belong?

Biocryst Pharmaceuticals Inc operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Biocryst Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Biocryst Pharmaceuticals Inc?

The PE ratio of Biocryst Pharmaceuticals Inc is N/A and the PB ratio is 56.59.